Search
for
Sort by
Research 61–90 of 875
- Alopecia Possibly Secondary to Topical Ophthalmic β-Blockers
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata
- Madarosis, milphosis, eyelash trichomegaly, and dermatochalasis
- Frontal fibrosing alopecia: a disease that remains enigmatic
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Acitretin-induced alopecia areata: a case report
- Frontal fibrosing alopecia: A multicenter review of 355 patients
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Frontal Fibrosing Alopecia
- Frontal fibrosing alopecia presenting with rapidly spreading facial papules in a premenopausal woman: Case report and review
- Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study
- Trichotillomania Mimicking Alopecia Areata in an Adolescent Girl: A Clinicopathologic Case Report
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
- The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Baricitinib regrows hair in adolescents with alopecia areata
- [[Translated article]]Low-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series
- Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Depression among Alopecia Areata Patients: Prevalence and associated factors in a Tunisian sample
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- 50524 Facebook groups provide support and product recommendations for patients using scalp cooling to prevent chemotherapy-induced alopecia: A survey study